ABSTRACT
Stunting affects one-in-five children globally and is associated with greater infectious morbidity, mortality and neurodevelopmental deficits. Recent evidence suggests that the early-life gut microbiome affects child growth through immune, metabolic and endocrine pathways, and microbiome perturbations may contribute to undernutrition. We examined early-life fecal microbiome composition and function in 875 stool samples collected longitudinally in 335 children from 1-18 months of age in rural Zimbabwe, from a cluster-randomized trial of improved water, sanitation, and hygiene (WASH), and improved infant and young child feeding (IYCF). Using whole metagenome shotgun sequencing, we examined the effect of the interventions, in addition to environmental or host factors including maternal HIV infection, on the succession of the early-life gut microbiome, and employed extreme gradient boosting machines (XGBoost) to model microbiome maturation and to predict child growth. WASH and IYCF interventions had little impact on the fecal microbiome, however children who were HIV-exposed but uninfected exhibited over-diversification and over-maturity of the early-life gut microbiome in addition to reduced abundance of Bifidobacteria species. Taxonomic microbiome features were poorly predictive of linear and ponderal growth, however functional metagenomic features, particularly B-vitamin and nucleotide biosynthesis pathways, moderately predicted both attained linear and ponderal growth and growth velocity. We find that the succession of the gut microbiome in a population at risk of stunting is unresponsive to WASH and IYCF interventions, but is strongly associated with maternal HIV infection, which may contribute to deficits in growth. New approaches targeting the gut microbiome in early childhood may complement efforts to combat child undernutrition.
One sentence summary The gut microbiome of rural Zimbabwean infants undergoes programmed maturation that is unresponsive to sanitation and nutrition interventions but is comprehensively modified by maternal HIV infection and can moderately predict linear growth.
Competing Interest Statement
TJE was paid a scientific consulting fee in relation to the analysis of the data presented here by Zvitambo Institute for Maternal and Child Health Research. RCR declares remittance from Abbott Nutrition Health Institute (March 2022) and Nutricia (May 2021) for public conference talks outside the submitted work. All other authors declare that they have no competing interests.
Clinical Trial
NCT01824940
Funding Statement
This study was funded by: -Bill & Melinda Gates Foundation (OPP1021542 and OPP1143707; JHH and AJP), with a subcontract to the University of British Columbia (20R25498; ARM) -United Kingdom Department for International Development (DFID/UKAID; JHH and AJP) -Wellcome Trust (093768/Z/10/Z, 108065/Z/15/Z; AJP) -Swiss Agency for Development and Cooperation (JHH and AJP) -US National Institutes of Health (2R01HD060338-06; JHH) -UNICEF (PCA-2017-0002; JHH and AJP). The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All SHINE mothers provided written informed consent. The Medical Research Council of Zimbabwe (MRCZ/A/1675), Johns Hopkins Bloomberg School of Public Health (JHU IRB # 4205.), and the University of British Columbia (H15-03074) approved the study protocol, including the microbiome analyses. The SHINE trial is registered at ClinicalTrials.gov (NCT01824940).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵11 Members of the SHINE Trial team who are not named authors are listed in https://academic.oup.com/cid/article/61/suppl_7/S685/358186
Data Availability
Raw sequencing reads are deposited in the European Bioinformatics Database under accession number PRJEB51728. Associated metadata from the larger SHINE trial will be uploaded to http://ClinEpiDB.org following publication of all primary manuscripts from the SHINE trial. Prior to that time, the data are housed on the ClinEpiDB platform at the Zvitambo Institute for Maternal and Child Health Research and available upon request from Ms. Virginia Sauramba (vsauramba{at}zvitambo.co.zw).
